【摘要】 背景与目的MMP-9、endostatin和VEGF是与多种恶性肿瘤有关的重要的血管生长调控因子。本研究的目的是分析非小细胞肺癌(NSCLC)患者血清MMP-9、endostatin、VEGF水平的临床意义。方法应用酶联免疫吸附法(ELISA)检测92例初治晚期NSCLC患者血清MMP-9、endostatin及VEGF水平,另有肺良性疾病对照组50例和健康对照组52例。结果肺癌患者治疗前血清中MMP-9、endostatin及VEGF水平明显高于健康人及肺良性疾病患者(P=0.000,P=0.000,P=0.000)。以健康人检测值x-+2s为临界值,MMP-9、endostatin及VEGF诊断NSCLC的敏感度分别为92.51%、88.32%和83.40%,特异度分别为79.10%、74.25%和75.63%。MMP-9、endostatin水平较高的肺癌患者生存期明显短于低MMP-9、en-dostatin的肺癌患者(P=0.0145,P=0.008)。部分患者化疗后检测三项指标,疗效达PR+SD的患者中,MMP-9水平下降组与上升组间的预后差异有统计学意义(P=0.0322)。结论肺癌患者血清中MMP-9、en-dostatin及VEGF水平显著增高,检测肺癌患者血清MMP-9、endostatin和VEGF水平对于指导临床肺癌诊断、估计预后有着重要意义。更多还原

【Abstract】 Background and objective Matrix metalloproteinase-9 (MMP-9), endostatin (ES) and vascular endothelial growth factor (VEGF) are important angiogenic regulators for many neoplasms. The aim of this study is to judge clinical and prognostic values of detection of serum MMP-9, ES and VEGF in patients with non-small cell lung cancer (NSCLC). Methods Serum levels of MMP-9, ES and VEGF were detected in 92 patients with NSCLC, 50 patients with pulmonary benign disease and 52 healthy controls by ELISA method. Results The serum levels of MMP-9, ES and VEGF in NSCLC patients were significantly higher than those in patients with pulmonary benign disease and healthy controls (P=0.000, P=0.000, P=0.000). The sensitivity and specificity of serum MMP-9 was 92.51% and 79.10% with a cutoff value of 117.17 μg/L, 88.32% and 74.25% for ES with a cutoff value of 100.31 μg/L, and 83.40% and 75.63% for VEGF with a cutoff value of 380.32 ng/L. Serum MMP-9 and ES levels were significant prognostic factors for lung cancer patients (P=0.0145, P=0.008). The change of serum MMP-9 level after chemotherapy was a useful indicator of prognosis for NSCLC patients (P=0.0322). Conclusion The serum levels of MMP-9, ES and VEGF are significantly increased in patients with NSCLC. They might be used as prognostic parameters in patients with NSCLC.更多还原